Last reviewed · How we verify
Standard heparin dose
Standard heparin dose is a Anticoagulant Small molecule drug developed by University of Utah. It is currently FDA-approved for Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism), Acute coronary syndrome, Atrial fibrillation for stroke prevention. Also known as: standard heparin anticoagulation.
Standard heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.
Standard heparin dose is used to treat conditions such as Venous Thromboembolic Event, Aneurysm, and Limb Ischemia, as well as to prevent complications in patients with Diffuse Large B Cell Lymphoma. The standard dose of heparin activates Antithrombin-III, a protein that inhibits blood clotting, by acting as an Antithrombin-III activator.
At a glance
| Generic name | Standard heparin dose |
|---|---|
| Also known as | standard heparin anticoagulation |
| Sponsor | University of Utah |
| Drug class | Anticoagulant |
| Target | Antithrombin III (enhancer); Thrombin (Factor IIa) and Factor Xa (indirect targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Heparin is an anticoagulant that works by binding to antithrombin III and dramatically increasing its ability to inactivate thrombin (Factor IIa) and Factor Xa. This prevents the formation of fibrin clots and the extension of existing clots. Heparin is typically administered intravenously or subcutaneously and has a rapid onset of action, making it suitable for acute thrombotic conditions.
Approved indications
- Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism)
- Acute coronary syndrome
- Atrial fibrillation for stroke prevention
- Prevention of thrombosis during cardiac surgery and extracorporeal circulation
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Thrombosis
- Osteoporosis (with prolonged use)
- Hyperkalemia
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial (NA)
- Dose for Reversal of Heparin After Cardiopulmonary Bypass (NA)
- Impact of CRRT on Serum Carnitine and Micronutrient Levels
- Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management (NA)
- A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (PHASE1)
- Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard heparin dose CI brief — competitive landscape report
- Standard heparin dose updates RSS · CI watch RSS
- University of Utah portfolio CI
Frequently asked questions about Standard heparin dose
What is Standard heparin dose?
How does Standard heparin dose work?
What is Standard heparin dose used for?
Who makes Standard heparin dose?
Is Standard heparin dose also known as anything else?
What drug class is Standard heparin dose in?
What development phase is Standard heparin dose in?
What are the side effects of Standard heparin dose?
What does Standard heparin dose target?
Related
- Drug class: All Anticoagulant drugs
- Target: All drugs targeting Antithrombin III (enhancer); Thrombin (Factor IIa) and Factor Xa (indirect targets)
- Manufacturer: University of Utah — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism)
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Also known as: standard heparin anticoagulation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing